For many investors, the experimental psychedelics industry may be too risky to invest in. Most companies in this sector are privately held, and psychedelic stocks are often volatile penny or OTC stocks.
Aside from being risky, these stocks can also be difficult to purchase. Most stocks will require you to have a brokerage account that offers access to OTC and international stocks, like Interactive Brokers.
For investors willing to take the risk, the best psychedelic stocks depend on your portfolio and investment goals—while volatility can be ideal for day traders, long-term investors will want to look to stocks with steadier gains over time.
We round up a selection of stocks in or related to the experimental drug industry, weighting the list more heavily towards popular mid- and large-cap stocks.
| Best stock | 1-year return | Market cap | Exchange | Volume | Buy on Questrade |
|---|---|---|---|---|---|
| Compass Pathways Plc (CMPS.US) | 211.47% | $1.5 billion (USD) | NASDAQ | 7,665,408 | Buy now |
| Definium Therapeutics (DFTX.US) | 348.84% | $5.8 billion (USD) | NASDAQ | 1,561,938 | Buy now |
| Cybin IncCommon Stock (HELP.US) | 41.15% | $504.6 million (USD) | NASDAQ | 2,794,788 | Buy now |
| ATAI Life Sciences BV (ATAI.US) | 72.32% | $2.7 billion (USD) | NASDAQ | 9,546,637 | Buy now |
| Psyched Wellness (PSYC.CN) | -50.00% | $4.1 million (CAD) | Canadian Securities Exchange | 16,000 | Buy now |
| Field Trip Health (FTRP.CN) | (data unavailable) | $210.8 million (CAD) | Canadian Securities Exchange | (data unavailable) | Buy now |
The experimental drug industry is affected by a range of complex factors such as trade policies, regulations, and fluctuating supply and demand. So when considering psychedelic stocks to buy, it's important that you have access to vital information about a company's financial health, leadership team, and market positioning.
Also keep in mind that, while volatility can be ideal for day traders, long-term investors will want to look for stocks to offer steadier gains over time.
A lot of factors go into picking the best psychedelic stocks. Stock performance can be impacted by factors like market conditions, company decisions and global events. Plus, what may be a strong psychedelic stock investment for one person might not be suitable for another.
That said, we rounded up this list of popular psychedelic stocks in or related to the experimental drug industry to help narrow down your options:
Keep in mind that this is not a "best" list or a recommendation. It highlights some psychedelic stocks for informational purposes only and does not indicate past or future performance or investment advice. We do not guarantee any investment performance.
We've outlined detailed company and stock performance details for each psychedelic stock below. Keep reading to decide if any of these companies are the right investment for you.
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa.
The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.
| Closing stock price | $13.58 |
|---|---|
| Market Capitalization | $1.5 billion |
| Earnings per share (TTM) | -$3.14 |
| 52-week stock price range | $3.97 – $15.40 |
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder.
The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.
| Closing stock price | $44.39 |
|---|---|
| Market Capitalization | $5.8 billion |
| Earnings per share (TTM) | -$2.50 |
| 52-week stock price range | $8.70 – $49.20 |
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders.
The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system.
| Closing stock price | $10.53 |
|---|---|
| Market Capitalization | $504.6 million |
| Earnings per share (TTM) | -$4.37 |
| 52-week stock price range | $3.76 – $9.12 |
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder.
It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD.
| Closing stock price | $7.22 |
|---|---|
| Market Capitalization | $2.7 billion |
| Gross profit (TTM) | $-54,607,000 |
| Revenue (TTM) | $3.5 million |
| Earnings per share (TTM) | -$2.84 |
| 52-week stock price range | $3.27 – $7.22 |
Psyched Wellness Ltd. produces and distributes mushroom-derived products and related consumer packaged goods in the United States. It offers a line of Amanita Muscaria-derived extracts to promote stress relief, relaxation, and assist with restful sleeping.
The company sells its products online.
| Closing stock price | C$0.01 |
|---|---|
| Market Capitalization | C$4.1 million |
| Gross profit (TTM) | C$189,792 |
| Revenue (TTM) | C$746,396 |
| Earnings per share (TTM) | -C$0.02 |
| 52-week stock price range | C$0.01 – C$0.03 |
Field Trip Health Ltd. engages in the development and delivery of psychedelic therapies. Its Research division is involved in the development of psychedelic molecules and conducting research on plant-based psychedelics.
The company also operates Field Trip Health clinics for psychedelic therapies in North America.
| Market Capitalization | C$210.8 million |
|---|---|
| Gross profit (TTM) | C$-8,403 |
| Revenue (TTM) | C$435,460 |
Compare special offers, low fees and a wide range of investment options among popular trading platforms in Canada. Note that the dollar amounts in the table below are in CAD.
To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score, the better the platform—it's that simple.
Learn how to buy SpaceX stock in Canada and see stock performance history over time.
We break down which companies hold Ethereum, why they’re doing it and what ETH treasuries mean for markets and investors.
Want to invest in the Euro Stoxx 50 in Canada? Explore investment platforms and popular Euro Stoxx 50 index funds.
Learn how to research stocks and find the right investment opportunities in 4 steps.
Find out the key differences between the Nasdaq Composite and the Nasdaq 100.
Here are the best Canadian investment newsletters to help you boost your investment knowledge and grow your wealth.
Here’s how the Nasdaq and NYSE are different and what you need to know before investing on either exchange.
Learn the rules of day trading in Canada before you dive into this full-time commitment.
These are the best renewable energy stocks to buy now in Canada.
If you want to make the most of your money or need advice on financial products, a financial advisor can help.
Finder’s unique algorithm found the 20 best TSX stocks to buy right now.
Learn how to navigate the ins and outs of the stock market with these popular online stock trading courses in Canada.
Find out how to invest in the S&P 500 in Canada—one of the world’s most popular stock indices—to diversify your portfolio.